2025

• patent2025/10/17

  Galliprant® Granted Supplementary Protection Certificate (SPC) in Belgium (BE)

  BE granted SPC for Galliprant® on September 5, 2025. The SPC extends the period of exclusive sales rights for Galliprant® until March 1, 2031. This grant in BE marks the 10th country in Europe, following Italy, Holland, Spain, Germany, France, Ireland, Greece, Poland, and Great Britain, and a five-year extension has been granted to all 10 countries where we applied for the extension within Europe.

• patent2025/07/29

  European Patent Office Grants AskAt a Patent for AAT-730 Salt & Crystal Forms

  AskAt received a communication under Rule 71(3) EPC dated June 26, 2025 from the European Patent Office, with which the grant of the European patent is proposed. The notice was issued in connection with European Patent Application No. 21891958.7 (Filing Date: November 11, 2021) for a salt and crystal forms patent for its CB2 agonist, AAT-730. In addition to Europe, salt and crystal forms patents have also been granted in Australia, Brazil, Canada, China, Israel, Japan, Korea, Mexico, New Zealand, and the U.S.

• company2025/06/01

  Headquarters Relocation

  We are pleased to inform you that the headquarters moved to the following address on June 1.
  
  New address: 4F STATION Ai, 1-2-32, Tsurumai, Showa-ku, Nagoya, Aichi 466-0064, Japan.

• patent2025/05/12

  AskAt Receives EP4 Antagonist (AAT-007) Salt & Crystal Forms Patent in the U.S.

  AskAt Inc. (Headquarters: Nagoya, Japan) received an Issue Notification from the United States Patent and Trademark Office (USPTO) dated April 30, 2025 for a salt and crystal forms patent for the company’s EP4 Antagonist, AAT-007. The Notification was issued in connection with Application Number 18/624,982 (Filing Date: July 11, 2019). This application will be issued as US Patent No. 12,295,962 on May 13, 2025.
  

• ir2025/03/24

  12th period financial statement release

  12th period financial statement release